drug · antibody
spartalizumab
Phase 3updated 3mo agoby $NVS NOVARTIS AG🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 14 investigational indications.
targets
Programmed cell death protein 1
all catalysts(0)
nothing on the calendar yet
Trials studying spartalizumab
- phase2Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
- EP1A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma
- phase2Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults
- phase1A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
- phase2Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
- phase1Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
- phase3A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
- phase2Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that